Pimecrolimus Cream Articles

Medivir renegotiates deal with Meda, receiving $45 million for US rights for Xerese; Meda passes this and Elidel to Valeant

30 June 2011

Meda buys global rights to Novartis’ Elidel for $420 million

7 April 2011

Further concerns on Novartis' Elidel

22 January 2007

Novartis' posts solid 2nd-qtr 2006 profit, despite heavy Chiron integration costs

24 July 2006

Astellas' net income for full-year 2005 reaches 103.6 billion yen

29 May 2006

Danger to patients from weak US Rx system: CU

12 December 2005

Pimecrolimus skin study yields encouraging results

12 September 2005

Oncology and cardiovascular drugs push Novartis' 2nd-qtr results

25 July 2005

Corgentech's eczema drug advances to Ph I/II

16 May 2005

FDA criticized for "unscientific scare-mongering" over new eczema drug

16 May 2005

Elidel provides long-term control of eczema

28 February 2005

EWGAD highlights Protopic as superior in atopic dermatitis

20 December 2004

Novartis beats expectations with 19% rise in 1st-half 2004 net income

26 July 2004

Promising new data for Fujisawa's Protopic

19 July 2004

Novartis increases stake in Roche; 2003 results strengthen global position

2 February 2004

Letter to the Editor

24 November 2003

Fujisawa and GSK in co-promotion deal

9 June 2003

Profits flat at Novartis despite sales growth

21 April 2003

Novartis' Elidel cleared in Switzerland

14 April 2003

UK NICE to view statins, antipsychotics, etc

7 April 2003

Novartis launches Elidel Cream in UK

24 March 2003

AstraZeneca files new data to US FDA on Crestor; possible approval in 2nd half

17 February 2003

2002's crop of new product launches backs up R&D fears

10 February 2003

Novartis in line with expectations for 2002, pharma growth holding strong

3 February 2003

Novartis' IBS treatment cleared in Canada, Brazil

25 March 2002

Tokyo pharma stocks - week to March 18

25 March 2002

Elidel works in 82% of adult eczema patients

4 March 2002

Tokyo pharma stocks - week to January 7

14 January 2002

Update: Novartis gets first approval for Elidel

7 January 2002

Novartis' Elidel cleared in first market

7 January 2002

Novartis' Elidel cleared in first market

14 December 2001

Novartis' pipeline still a leader in pharma sector, despite recent setbacks

8 November 2001

Novartis' Elidel works in childhood eczema

11 September 2001

Novartis files for EU approval of Elidel

26 June 2001

Letter to the Editor

14 June 2001

Fujisawa outlines its current product development and expansion plans

19 March 2001

Novartis R&D day updates prospects for key pipeline drugs

7 December 2000

Novartis' Elidel effective in young children

16 October 2000

Novartis says 25% chance Zelmac NDA will not be accepted

22 February 2000

Novartis Trileptal approvable in USA; firm building broad franchise in

30 September 1999

Novartis highlights clinical projects to turn around fortunes at its pharma

27 September 1999

Novartis upbeat at biannual R&D update

23 September 1999

Showing 1-42 of 42 articles

Go to beginningPrevious
  • 1
NextGo to end